Adverse clinical events after percutaneous coronary intervention in very elderly patients with acute coronary syndrome
- PMID: 38839727
- DOI: 10.1007/s12928-024-01020-6
Adverse clinical events after percutaneous coronary intervention in very elderly patients with acute coronary syndrome
Abstract
The number of very elderly patients with acute coronary syndrome (ACS) is increasing. Therefore, owing to the need for evidence-based treatment decisions in this population, this study aimed to examine the clinical outcomes during 1 year after percutaneous coronary intervention (PCI) in very elderly patients with ACS. This prospective multicenter observational study comprised 1337 patients with ACS treated with PCI, classified into the following four groups according to age: under 60, <60 years; sexagenarian, ≥60 and <69 years; septuagenarian, ≥70 and <80 years; and very elderly, ≥80 years. The primary endpoint was a composite of the first occurrence of all-cause death, nonfatal myocardial infarction, nonfatal stroke, and bleeding within 1 year after PCI. We used the sexagenarian group as a reference and compared outcomes with those of the other groups. The incidence of the primary endpoint was significantly higher in the very elderly group than in the sexagenarian group (36 [12.7%] vs. 24 [6.9%], respectively; hazard ratio, 1.94; 95% confidence interval: 1.16-3.26; p = 0.012). The higher incidence of the primary endpoint was primarily driven by a higher incidence of all-cause death. When the multivariable analysis was used to adjust for patient characteristics and comorbidities, no difference was observed in the primary endpoint between the very elderly and sexagenarian groups (p = 0.96). The incidence of adverse events after PCI, particularly all-cause death, in very elderly patients with ACS was high. However, if several confounders are adjusted, comparable outcomes may be expected within 1 year after PCI among this population.
Keywords: Acute coronary syndrome; All-cause death; Elderly patients; Percutaneous coronary intervention.
© 2024. The Author(s) under exclusive licence to Japanese Association of Cardiovascular Intervention and Therapeutics.
Similar articles
-
[Age-related differences in the management and outcome of acute coronary syndrome under the chest pain center model: a multicenter retrospective study].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Mar;33(3):318-323. doi: 10.3760/cma.j.cn121430-20200806-00565. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 33834973 Chinese.
-
Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study.Drugs Aging. 2011 May 1;28(5):369-78. doi: 10.2165/11587170-000000000-00000. Drugs Aging. 2011. PMID: 21542659
-
Outcomes of Nonagenarians With Acute Coronary Syndrome.J Am Med Dir Assoc. 2022 Jan;23(1):81-86.e4. doi: 10.1016/j.jamda.2021.04.027. Epub 2021 Jun 29. J Am Med Dir Assoc. 2022. PMID: 34197794
-
Net clinical benefit of clopidogrel versus ticagrelor in elderly patients carrying CYP2C19 loss-of-function variants with acute coronary syndrome after percutaneous coronary intervention.Atherosclerosis. 2024 Mar;390:117395. doi: 10.1016/j.atherosclerosis.2023.117395. Epub 2023 Dec 13. Atherosclerosis. 2024. PMID: 38114408
-
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.Health Technol Assess. 2015 Apr;19(29):1-130. doi: 10.3310/hta19290. Health Technol Assess. 2015. PMID: 25896573 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Miscellaneous